- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
STRATA Skin Sciences Announces Licensing Agreement for Certain MelaFind Assets
STRATA Skin Sciences (NASDAQ:SSKN) has announced a fully paid exclusive and perpetual license agreement related to its discontinued MelaFind device. As quoted in the press release: STRATA retains all intellectual property rights related to the MelaFind device and product line, including patents, design files and PMA approval to market. The strategic entity will be allowed …
STRATA Skin Sciences (NASDAQ:SSKN) has announced a fully paid exclusive and perpetual license agreement related to its discontinued MelaFind device.
As quoted in the press release:
STRATA retains all intellectual property rights related to the MelaFind device and product line, including patents, design files and PMA approval to market. The strategic entity will be allowed exclusive rights to the de-identified digital images.
“We are pleased to come to agreement with this licensing partner for the de-identified images related to the MelaFind device. Rationalizing the MelaFind assets is one step in our ongoing strategic turn-around efforts following our recent financing,” said Dr. Dolev Rafaeli, chief executive officer of STRATA. “While we will look for additional licensing opportunities and continue to evaluate potential M&A opportunities, our main focus is on rebuilding our XTRAC network, expanding internationally and executing on our proven revenue strategy.”
The perpetual license agreement is subject to customary closing conditions.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.